Toviaz

Toviaz is a prescription medicine approved to treat symptoms of an overactive bladder. By relaxing the muscles of the bladder, this medication can help reduce the frequency of wetting accidents and prevent frequent urination. The drug comes in the form of extended-release tablets that are taken just once a day. While most people tolerate the medication well, potential side effects include indigestion or heartburn, constipation, and dry mouth.

Toviaz Medication Information

What Is Toviaz?

Toviaz^™ (fesoterodine fumarate) is a prescription overactive bladder medication. Specifically, it is approved to help treat the following symptoms of an overactive bladder:

Sudden, frequent urges to urinate
Frequent urination (usually defined as needing to go more than eight times in 24 hours)
Leaking accidents (known as urinary incontinence or urge incontinence).

(Click Toviaz Uses for more information, including possible off-label uses.)

Who Makes It?

Toviaz is made by Schwarz Pharma Produktions and is marketed and distributed by Pfizer, Inc.

How Does Toviaz Work?

An overactive bladder is often due to bladder muscle contractions that are too frequent and uncontrollable. Toviaz works by helping to relax the muscles of the bladder, thereby helping to relieve many of the symptoms of an overactive bladder. Specifically, Toviaz is part of a group of medications known as antimuscarinics or anticholinergics. It works by blocking specific receptors (called muscarinic receptors) in the bladder.

Clinical Effects

Studies have shown Toviaz to be effective for relieving many of the symptoms of an overactive bladder. In clinical studies, people who took this medication experienced a significant reduction in the frequency of wetting accidents. Additionally, people who took the medication used the bathroom less frequently and were able to pass more urine each time they used the bathroom (the frequent muscle contractions of an overactive bladder usually prevent the bladder from holding a normal amount of urine).

(Toviaz Continued: Page 2)